Aptar’s UDS: The Trusted Platform for Nasal Drug Delivery

Decades of Trust: Aptar Pharma’s UDS Platform in Nasal Drug Delivery

This article explores the enduring success of Aptar Pharma’s Unidose System (UDS), a nasal drug delivery platform that has become a global benchmark for reliability, regulatory approval, and patient-centric design. With over 30 years of real-world use, 30+ market references, and hundreds of millions of units delivered, UDS continues to lead the way in single-use nasal drug delivery.

A Proven Platform for Critical Therapies

Aptar Pharma’s UDS is the only nasal spray system approved by both the US FDA and the European Medicines Agency (EMA), and it is the delivery platform behind some of the world’s most impactful therapies. Designed for intuitive, one-handed administration in any position, UDS eliminates the need for priming, shaking, or specialized handling. Its compact, ready-to-use format makes it ideal for use by patients, caregivers, or even bystanders in emergency situations such as opioid overdose, anaphylaxis, or hypoglycemia.

The UDS platform is engineered to deliver each dose with exceptional precision, supporting partners in achieving 99.999% reliability. Its tamper-evident design and rigorous microbiological testing ensure product integrity and user confidence—critical attributes for therapies where speed, safety, and simplicity are essential.

Adaptable Across Indications

More than just a device, UDS is a scalable platform that supports a wide range of therapeutic applications—from the chronic central nervous system and endocrine disorders to acute, life-threatening conditions. Its adaptability has enabled successful collaborations across diverse indications, with each therapy benefiting from a tailored approach that considers both patient needs and regulatory expectations.

Aptar Pharma’s nasal drug delivery platform offers a variety of customization options, including liquid or powder formulations, unidose or bidose formats, and design flexibility to suit specific clinical and patient use cases. This versatility provides a unique opportunity to reposition existing drugs or bring new therapies to market, enabling partners to extend product lifecycles and respond to unmet patient needs.

Regulatory and Commercial Readiness

The UDS platform offers a validated path to market, with approvals of various active pharmaceutical ingredients by both the FDA and EMA. Its proven machinability ensures seamless integration into existing manufacturing operations, reducing development risk and accelerating time to market.

Beyond the device itself, Aptar Pharma provides comprehensive support throughout the product lifecycle. Aptar Pharma service include formulation development, regulatory guidance, and post-launch support such as device training, patient onboarding, and digital health solutions. This full-spectrum support helps partners navigate complex development pathways and achieve long-term product success.

Global Supply and Strategic Partnerships

Aptar Pharma’s global, dual-sourced manufacturing network ensures consistent supply and quality assurance across markets. Through strategic collaborations with contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs), Aptar offers flexible production capabilities—from clinical-scale batches to high-volume commercial supply.

This infrastructure supports scalability and reliability, making UDS a dependable choice for pharmaceutical companies looking to launch or expand nasal drug delivery programs.

Why UDS Matters for Drug Developers

As therapies become more complex and patient expectations rise, dependable delivery systems play a central role in successful treatment outcomes. Whether repurposing a well-established molecule or launching a novel therapy, UDS offers a regulatory-approved platform that has helped leading developers bring critical treatments to market safely and efficiently.

Its long-standing regulatory and commercial success, combined with its adaptability and full lifecycle support, makes UDS a strategic asset for pharmaceutical companies aiming to innovate in nasal drug delivery.

Looking Ahead

Aptar Pharma remains committed to investing in innovation, with a strong focus on nose-to-brain potential and next-generation solutions that expand what’s possible for partners. As the demand for non-invasive, fast-acting therapies continues to grow, UDS is well-positioned to support the future of nasal drug delivery.

For pharmaceutical developers seeking a proven, flexible, and globally trusted nasal delivery solutions, Aptar Pharma’s UDS platform offers a compelling foundation for success.